- Home
- PDT vs KROS Comparison
PDT vs KROS Comparison
Compare PDT & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PDT | KROS |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 653.2M | 584.9M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PDT | KROS |
|---|---|---|
| Price | $13.14 | $11.72 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.86 |
| AVG Volume (30 Days) | 106.8K | ★ 275.2K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.00 |
| EPS | N/A | ★ 2.30 |
| Revenue | N/A | ★ $243,864,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,751.79 |
| P/E Ratio | ★ N/A | $4.99 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.53 | $10.42 |
| 52 Week High | $13.65 | $22.55 |
Technical Indicators
Market Signals| Indicator | PDT | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 48.60 | 50.75 |
| Support Level | $13.03 | $10.56 |
| Resistance Level | $13.18 | $12.65 |
| Average True Range (ATR) | 0.12 | 0.36 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 31.43 | 69.75 |
Price Performance
Historical ComparisonAbout PDT John Hancock Premium Dividend Fund
John Hancock Premium Div Fund is a United States-based closed-end management investment company. It seeks to provide a high current income consistent with modest capital growth. The fund will pursue its objective by investing in a diversified portfolio comprised of dividend-paying preferred securities and common equity securities. The portfolio composition of the fund consists of preferred securities, common stocks, corporate bonds, capital preferred securities, and short-term investments.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.